Patients with atrial fibrillation (AF) who use a direct oral anticoagulant (DOAC) dose that’s inconsistent with US Food and Drug Administration labeling—a practice believed, in many cases, to be ...
Obesity can alter the action of many types of medications in ways affecting safety and/or efficacy, but this often isn’t mentioned in the labels. Experts in obesity and pharmacology are trying to ...
PORTLAND, Ore. (KOIN) — Painkillers are being recalled across the United States after a manufacturer’s mislabeling has led to a risk that some patients could be taking double what they were prescribed ...
Dr Coney expands on the role and impact of approved label dosing of faricimab. Jim Kenney, RPh, MBA: Dr Coney, what has been your experience in the real-world setting with faricimab? Does the approved ...
It is an exciting time to be a medical dermatologist, with the ongoing development of numerous safe and effective systemic treatments for several complex medical dermatologic diseases. For example, ...
Please provide your email address to receive an email when new articles are posted on . In this video, Matthew M. Heeney, MD, discussed results from the Solace-Kids trial, which was presented at ASH ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA® (sodium zirconium cyclosilicate) to include a dosing ...
Among patients hospitalized for atrial fibrillation (AF) or flutter, prescription of an off-label dose of a direct oral anticoagulant (DOAC) at discharge remains relatively common, according to data ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window It is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback